Back to Peter Attia MD

399 - The evolution of Alzheimer's disease and dementia care | Gayatri Devi, M.D.

Peter Attia MDJuly 13, 20261h 58m

Topics43

Introduction and Background0:00 Evolution of Understanding Dementing Conditions1:30 Spectrum Nature of Dementia and Alzheimer's Disease4:02 Pathophysiology and Disease Cascade8:33 Viral Inflammation and Neuroinflammation10:30 Patient Evaluation and Practice15:01 Lumbar Puncture vs. Blood Biomarkers20:30 Comprehensive Testing Timeline22:01 Integrating Results and Creating Treatment Plans22:31 Name Recall Difficulties27:30 Episodic vs. Semantic Memory31:11 Sex Differences in Alzheimer's Prevalence32:31 Biomarker Testing and Diagnostic Criteria38:33 Cautionary Case: Blood Test Misdiagnosis40:01 Preclinical Testing in High-Risk Individuals44:01 APOE Genotype and Lifetime Risk47:02 Treatment of a Preclinical High-Risk Patient49:02 Anti-Amyloid Monoclonal Antibodies51:31 Slow Titration Protocol and ARIA Risk54:32 Clinical Effect Size and Timing of Treatment56:32 Evaluating New Alzheimer's Drugs1:01:02 Costs of Lecanemab and Donanemab1:02:02 ARIA Risk and APOE Genotype1:03:30 Mechanism of ARIA1:04:32 Monitoring and Symptomatic vs. Radiographic ARIA1:06:30 Managing ARIA1:08:30 Limitations of Current Clinical Trials and Proposed Approaches1:10:31 Future Directions for Monoclonal Antibodies1:13:00 Dramatic Responder Cases1:13:34 Pre-Monoclonal Antibody Treatment Approaches1:16:00 GLP-1 Agonists and Dementia Risk1:21:01 Vascular Dementia1:22:30 Lewy Body Disease1:25:31 APOE4 and Alpha-Synuclein in Lewy Body Disease1:28:01 Distinguishing Lewy Body Disease from Parkinson's Disease1:31:26 Diagnostic Tools and Treatment Differences1:34:00 Treatment Considerations for Lewy Body Disease1:36:31 Risk Factors for Lewy Body Dementia1:38:32 Gender Distribution and Menopause-Related Cognitive Impairment1:40:30 Hormone Therapy Decisions and Patient Perspectives1:44:30 Estrogen Administration Preferences1:49:30 Evolution of Clinical Beliefs1:50:00 Future Directions and Hopes1:52:30

In a Nutshell

Dr. Gayatri Devi describes Alzheimer's as a heterogeneous spectrum driven by inflammation, amyloid, tau, and synaptic loss, with high-functioning patients often masking pathology for years through cognitive reserve. Early, personalized treatment using anti-amyloid monoclonal antibodies (lecanemab, donanemab), cholinesterase inhibitors, memantine, TMS, vascular risk control, and hormone therapy in appropriate women can meaningfully slow or stabilize disease, especially when started before advanced tau or synaptic damage. Diagnosis must combine biomarkers with clinical function rather than rely on blood tests alone, and mixed pathologies like vascular disease and Lewy bodies are the norm rather than exception.

AI-Generated Notes

These notes were generated by AI and may contain inaccuracies.

Dr. Gayatri Devi is a neurologist and psychiatrist boarded in multiple specialties including neurology, psychiatry, brain injury medicine, pain medicine, and behavioral neurology, with her subspecialty focus being memory disorders from a neurological perspective.

Two major shifts have occurred in Dr. Devi's understanding of dementing conditions over her career. First, all dementing conditions, particularly Alzheimer's disease, present variably depending on the individual and comorbidities, creating a spectrum aspect that many people fail to recognize. Dementias are not an all-or-nothing disease but span from very mild impairment that doesn't worsen to severe impairment that deteriorates rapidly. Second, the field is now at a transformative point where many different treatment approaches exist, allowing personalized medication combinations and disease-modifying drugs that can alter disease course.

Dementia is the umbrella term referring to loss of connectivity between brain cells resulting in loss of function as a progressive condition. Alzheimer's disease is the most common type and is defined as synaptic loss of connectivity driven by extra-neuronal amyloid plaques, intra-neuronal neurofibrillary tangles, and inflammation in supporting microglial cells and other glial cells of the brain substrate. Diagnosis is challenging because high-functioning, intelligent individuals with good brain reserve can compensate effectively and maintain performance despite moderate or even severe pathology.

Subtypes of Alzheimer's Disease

Alzheimer's disease subtypes depend on which brain region the pathology predominantly affects. Memory-predominant Alzheimer's differs from visual-spatial predominant forms. Comorbid brain conditions such as Lewy body disease, TDP43 pathology, or hippocampal sclerosis inform how the disease presents in each person.

Diagnostic Approaches

Two schools of thought exist regarding diagnosis. One group maintains that biological biomarkers alone suffice for diagnosis. The other requires biomarkers plus clinical symptoms and functional deficit. Key biomarkers include amyloid, tau, and increasingly neuroinflammation.

The traditional understanding held that amyloid was the first abnormality beginning in the brain, appearing up to two to three decades before clinical symptoms. Current understanding suggests inflammatory pathway changes may predate amyloid deposition. The sequence appears to be neuroimmunological changes, followed by amyloid, then tau, ultimately causing synaptic dysfunction where connections between nerve cells deteriorate, leading to cognitive changes over decades.

Sign in to read the full notes

Get access to AI-generated notes, topic timestamps, and more.